UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Today's Latest Price: $25.36 USD
0.14 (-0.55%)
Updated Jul 2 4:00pm
Add URGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
URGN Stock Summary
- With a one year PEG ratio of 0.31, UroGen Pharma Ltd is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 5.51% of US stocks.
- For URGN, its debt to operating expenses ratio is greater than that reported by merely 0.34% of US equities we're observing.
- URGN's price/sales ratio is 31,830.31; that's higher than the P/S ratio of 100% of US stocks.
- Stocks that are quantitatively similar to URGN, based on their financial statements, market capitalization, and price volatility, are IMMU, GENE, CYAD, ADVM, and NK.
- Visit URGN's SEC page to see the company's official filings. To visit the company's web site, go to www.urogen.com.
URGN Daily Price Range
URGN 52-Week Price Range
URGN Stock Price Chart Technical Analysis Charts
URGN Price/Volume Stats
| Current price | $25.36 | 52-week high | $37.08 |
| Prev. close | $25.50 | 52-week low | $13.12 |
| Day low | $24.89 | Volume | 147,760 |
| Day high | $25.87 | Avg. volume | 220,269 |
| 50-day MA | $25.45 | Dividend yield | N/A |
| 200-day MA | $26.43 | Market Cap | 529.95M |
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
Loading social stream, please wait...